To provide access to palbociclib to post-menopausal women with HR-positive, HER2-negative advanced breast cancer who are deemed appropriate for letrozole therapy (Canada: first-line patients only).

This study is currently available in Canada only.

Inclusion Criteria:

• Post-menopausal women 18 years of age or above with proven diagnosis of advanced adenocarcinoma of the breast (locoregionally recurrent or metastatic disease)
• ER-positive and/or PR-positive tumor based on local laboratory results
• HER2-negative tumor based on local laboratory results
• Patients must be appropriate candidates for letrozole therapy (Canada: first-line patients only)

Exclusion Criteria:

• Patients who have previously participated in a palbociclib trial or who have received prior treatment with any CDK inhibitor